Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • New GSK shingles...

    New GSK shingles vaccine off to strong start in key US market

    Written by Ruby Khatun Khatun Published On 2018-04-12T09:45:33+05:30  |  Updated On 16 Aug 2021 4:57 PM IST

    LONDON: GlaxoSmithKline's (GSK) new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.


    The healthy take-up comes at the expense of Merck & Co's older and less effective product Zostavax, which has seen a slump in demand.


    The U.S. Centers for Disease Control and Prevention has recommended here Shingrix over Zostavax in adults 50 years and older, spurring demand for the GSK vaccine.


    Deutsche Bank analysts said on Tuesday the prescription data to mid-March implied "a very strong launch", even though the figures compiled by health information company IQVIA capture only 50 to 60 percent of the market.


    A GSK spokesman declined to comment on the Shingrix launch ahead of the company's first-quarter results on April 25, when sales of the vaccine are likely to be a focus for investors.


    Current consensus market forecasts point to Shingrix sales of less than 200 million pounds ($280 million) this year, which may prove to be an underestimate in the light of the positive market reception.


    Zostavax's worldwide sales were $668 million last year and analysts are betting GSK can better that, with consensus for 2024 of $1.8 billion, according to Thomson Reuters data.


    Adding to U.S. sales momentum is the fact that Shingrix can now be obtained at thousands of pharmacies, with CVS Health last month offering it at all its locations and Walgreens Boots Alliance making it available at most Walgreens and Duane Reade stores.


    GSK has high hopes for Shingrix, which it expects to become its biggest single vaccine over time. The more than 100 million adults eligible for vaccination in the United States represent a key opportunity.


    Chief Executive Emma Walmsley and her pharmaceuticals head Luke Miels have made sales of Shingrix in major markets a top priority as the British drugmaker adopts a more focused commercial approach.


    The shingles vaccine was also approved in Europe and Japan on March 23.


    Shingrix is given in two doses, separated by two to six months, while Zostavax is a single shot. Ensuring patients adhere to the two-shot regimen will be important in achieving the vaccine's full sales potential.



    Shingles is caused by reactivation of the varicella-zoster virus that is also responsible for chickenpox. Nearly all adults over 50 have the virus dormant in their nervous system and are at risk of it being reactivated with advancing age.

    ($1 = 0.7062 pounds)












    (Reporting by Ben Hirschler; Editing by Alexandra Hudson)









    CVS HealthEmma WalmsleyGlaxoSmithKlineGSKMerckshingles vaccineShingrixUS marketZostavax
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok